This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
Trade Parameters
Observations – For
Observations – Against
Attractive technical set-up with bullish breakout and potential bullish flag pattern. US tax reform could aid companies with major US exposure, such as AZN, while provision to remove some aspects of Affordable Care Act (Obamacare) may aid pharmaceutical names. Steady stream of positive trials and stateside drug approvals proving supportive of recent rally.
Consensus is bullish on the one of the most closely watched UK 100 companies, with 87% of brokers suggesting to ‘Buy’ or ‘Hold’ the shares. The 12-month broker target of 5488p is well above our trade limit, while October highs resistance is 60p above our modest target.
Next Event: FY 2018 Results, 2 Feb
Latest Broker 12-Month Consensus: 61% Buy, 26% Hold, 13% Sell (full breakdown on request)
Source: DowJones Newswires, Reuters News, Bloomberg or Company Press releases
This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance. Prepared by Michael van Dulken, Head of Research